NANOTEST
Development of methodology for alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics
| Coordinatore | NORSK INSTITUTT FOR LUFTFORSKNING
Organization address
address: Instituttveien 18 contact info |
| Nazionalità Coordinatore | Norway [NO] |
| Totale costo | 3˙933˙271 € |
| EC contributo | 2˙994˙383 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-FP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-04-01 - 2012-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
NORSK INSTITUTT FOR LUFTFORSKNING
Organization address
address: Instituttveien 18 contact info |
NO (KJELLER) | coordinator | 0.00 |
| 2 |
"NATIONAL CENTER FOR SCIENTIFIC RESEARCH ""DEMOKRITOS"""
Organization address
address: Patriarchou Gregoriou Str. contact info |
EL (AGHIA PARASKEVI) | participant | 0.00 |
| 3 |
ACONDICIONAMIENTO TARRASENSE ASSOCIACION
Organization address
address: CARRER DE LA INNOVACIO 2 contact info |
ES (TERRASSA) | participant | 0.00 |
| 4 |
ADVANCELL ADVANCED IN VITRO CELL TECHNOLOGIES S.A.
Organization address
address: C/Baldiri Reixac 10-12 contact info |
ES (BARCELONA) | participant | 0.00 |
| 5 |
HOSPICES CANTONAUX CHUV
Organization address
address: Rue du Bugnon 21 contact info |
CH (LAUSANNE) | participant | 0.00 |
| 6 |
INSTITUTE OF OCCUPATIONAL MEDICINE
Organization address
address: Research Avenue North, Riccarton 45 contact info |
UK (EDINBURGH) | participant | 0.00 |
| 7 |
JRC -JOINT RESEARCH CENTRE- EUROPEAN COMMISSION
Organization address
address: Rue de la Loi 200 contact info |
BE (BRUSSELS) | participant | 0.00 |
| 8 | KOBENHAVNS UNIVERSITET | DK | participant | 0.00 |
| 9 |
SLOVENSKA ZDRAVOTNICKA UNIVERZITA V BRATISLAVE
Organization address
address: LIMBOVA 12 contact info |
SK (BRATISLAVA) | participant | 0.00 |
| 10 |
UNIVERSITA CA' FOSCARI VENEZIA
Organization address
address: DORSODURO 3246 contact info |
IT (VENEZIA) | participant | 0.00 |
| 11 |
UNIVERSITE PARIS DIDEROT - PARIS 7
Organization address
address: RUE THOMAS MANN 5 contact info |
FR (PARIS) | participant | 0.00 |
| 12 |
University Hospitals Bristol NHS Foundation Trust
Organization address
address: "Trust Headquarters, Marlborough Street" contact info |
UK (BRISTOL) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Nanoparticles (NP) have unique, potentially beneficial properties, but their possible impact on human health has not been adequately assessed. The main goal of this proposal is to develop alternative high-throughput testing strategies using in vitro and in silico methods to assess the toxicological profile of NP used in medical diagnostics. Our specific aims are to: 1. Define NP properties and fully characterize NP to be used 2. Study NP interactions with molecules, cells and organs and develop in vitro methods to study the toxicological potential of NP 3. Validate in vitro findings in short-term in vivo models and study particle effects in animals and (ex vivo) in humans to assess individual susceptibility to NP 4. Develop in silico models of NP interactions Experimental work is structured in 4 WPs to address NP characterisation and key elements in evaluation of NP uptake, exposure and toxicology. NANOTEST integrates the investigation of toxicological properties and effects of NP in several target systems by developing a battery of in vitro assays using cell cultures, organotypic cell culture and small organ fragments (ex vivo) derived from different biological systems; blood, vascular system, liver, lung, placenta, digestive and central nervous systems. As NP action is likely to involve oxidative stress we will focus on the cross-cutting areas of inflammation, cellular toxicity, immunotoxicity, genotoxicity and related endpoints. Following development of SOP and generation of a common database and in parallel with in silico assays (QSAR, PBPK modelling), NanoTest will evaluate toxic effects and interactions of NP used in nanomedicine. Results will be validated in an experimental ethically approved in vivo model. The most advanced and standardised techniques will be adapted for automation and prepared for validation by ECVAM. Separate WPs will be dedicated to dissemination and to effective administrative and scientific management.'